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Abstract 
Background: Metformin is used to lower blood sugar in patients with 
type II diabetes. Recent research showed that metformin has effects on 
cancer cell growth. Studies show that metformin can induce apoptosis 
in certain cancer cell lines. In this study, we examined the effect of 
metformin on apoptosis in the T47D breast cancer cell line. 
Methods: The T47D breast cancer cell line was selected and 
purchased from the Pasteur Institute (Tehran, Iran). Cells were treated 
with doses of 5, 10, and 50 μM of metformin at 24, 48, and 72 hours. 
The transcription levels of genes involved in apoptosis, including 
caspase-3, -8, -9, and PARP-1, were evaluated by real-time PCR. 
Results: The results of this study showed that at all three doses (5, 10, 
and 50 μM) of metformin and at three times (24, 48, and 72 h), the 
expression of caspase-8 and caspase-9 were increased. Also, at all 
doses metformin increased the expression of PARP-1 at 48 and 72 
hours, but at 24 hours the expression of PARP-1 was not affected. 
Conclusions: These results indicate that metformin does not affect 
expression of caspase-3 at any dose or time point. This study showed 
that metformin, by increasing the transcription of caspase-8 and 
caspase-9, causes cell death through apoptosis. 
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Introduction 
Breast cancer is the most common cancer in women and 
the leading cause of cancer death in women 40–44 years old. 
This malignancy is responsible for 33% of female cancers and 
19% of cancer-related deaths. Evidence shows a steady 
increase in the prevalence of breast cancer in the mid-1940s1,2. 
Three methods are used for breast cancer treatment: surgery, 
chemotherapy, and radiotherapy.3 Recent studies have focused 
on drugs that can induce apoptosis in cancer cells. These drugs 
may be known drugs with different indications for the 
treatment of cancer. Metformin is a drug used to lower blood 
glucose in patients with type II diabetes. Anti-diabetic activity 
occurs through activation of AMPK (AMP-activated protein 
kinase) and the subsequent reduction in liver glucose and 
increase glucose uptake in skeletal muscle. The effects of 
biguanides, such as metformin, on the metabolic effects in non-
diabetic cancer patients have been examined.4,5 Reports suggest 
that patients with type 2 diabetes who were prescribed 
metformin compared with patients who did not use metformin 
are less likely to get breast cancer.5 Treatment with metformin 
reduces the size and distribution of breast cancer in female 
transgenic HER-2/neu mice6 and reduces the effects of 
carcinogens that cause pancreatic cancer in rats. Evidence 
suggests that metformin inhibits growth in cultured breast, 
colon, prostate, and glioma cancer cells.7-10 Apoptosis is a 
programmed cell death that plays a critical role in normal and 
pathological development of a wide range of tissue and results 
in shrinkage of cytoplasm and fragmentation of cell nucleus. In 
most cancer cells, apoptosis is blocked, which allows malignant 
cells to survive despite their genetic and morphological 
variation. Therefore, the search for substances that can initiate 
apoptosis in tumor cells a new strategy in anti-cancer drug 
discovery.1,2,11-14 Most drugs that induce apoptosis are often 
targeted to mitochondria and increase caspase activation. PARP 
is a nuclear protein implicated in DNA repair and is the earliest 
protein cleaved to a specific 89 kDa fragment (cleaved PARP) 
during apoptosis.15 In some cells, such as placental cells, it was 
revealed that cleavage of PARP by caspase-3 prevents PARP 
from repairing damaged DNA; this lack of repair can lead to 
apoptosis.15 Therefore, in this study, the effect of metformin on 
genes involved apoptosis in the breast cancer cell line T47D 
was studied. 
Materials and Methods 
The human breast cancer cell line T47D (Cell Bank Code: 
NCBI: C203) was cultured in DMEM supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(10,000 units of penicillin/ml and 10 mg/ml streptomycin) in an 
incubator at 37°C in a humidified atmosphere containing 5% 
CO2. Twenty-four hours before the test, a million cells in 
volume of 5 ml were added to each flask and were incubated 
for 24 h. After the incubation period, three flasks for each dose 
of metformin (5, 10, 50 μM) and control conditions were 
evaluated at 24, 48, and 72 h of treatment. At these time points, 
cells were counted and collected. After cell counting, cells 
were separated from the culture medium by centrifugation. The 
pellet was kept for one hour at −20 °C. Then, RNA was 
e tracted and kept at −70°C.  
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In this study, total RNA from control and treated T47D 
cells was extracted using RNeasy Plus Mini Kit purchased 
from Qiagen (Germany) according to the instructions that came 
in the kit. The concentration and purity of RNA were 
determined by measuring the absorbance at 260 nm of the 
extracted samples using Picodrop. Integrity and size 
distribution of total RNA was investigated by agarose gel 
electrophoresis with gels stained with SYBR Green.  
In this study, cDNA was synthesized by a kit (QuantiTect 
Reverse Transcription 50 reaction) purchased from Qiagen 
(Germany) according to instructions that came in the kit. 
Primers corresponding to GAPDH (internal control), 
caspase-3, caspase-8, caspase-9, and PARP-1 were designed 
using Gene Runner software. The suitability of the primers 
confirmed with BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) 
in order to find amplified fragment length and confirm that it 
has no non-specific binding sites on the same gene or positions 
of similar sequences in other species. The primers used were 
appropriate, and protected areas were selected in order to avoid 
errors caused by amplification of genomic DNA binding region 
of exon–exon. 
Table 1: Profile primers 
Official 
name 
Primer sequences(5′-3′) Tm(°C) GCcontent 
Caspase 8 Forward: 
GAAAAGCAAACCTCGGGGATAC 
Reverse: 
CCAAGTGTGTTCCATTCCTGTC 
57.6 
55.5 
50% 
50% 
Caspase 9 Forward: 
CCAGAGATTCGCAAACCAGAGG 
Reverse: 
GAGCACCGACATCACCAAATCC 
59.5 
60 
54.6% 
54.6% 
GAPDH Forward: 
TGCACCACCAACTGCTTAGC 
Reverse: 
GGCATGGACTGTGGTCATGAG 
55.9 
57.3 
55% 
57.1% 
Caspase 3 Forward: 
CTGGACTGTGGCATTGAGAC 
Reverse: 
ACAAAGCGACTGGATGAACC 
58.55 
58.48 
55% 
50% 
PARP-1 Forward: 
GGAAAGGGATCTACTTTGCCG 
Reverse: 
TCGGGTCTCCCTGAGATGTG 
60.5 
61.2 
55% 
60% 
To investigate the quantitative expression of caspase-3, 
caspase-8, caspase-9, and PARP-1, quantitative real-time PCR 
reactions with the same conditions for all genes were done by 
real-time PCR (ABI-7300) using a SYBR Green PCR kit (ABI, 
USA) based on the kit instructions. Study of real-time PCR for 
the six genes listed in different groups was performed using the 
2−ΔΔCt method. 
Data was entered into the statistical software SPSS16 and 
was analyzed using ANOVA, and Tukey's test. 
Results  
In the present study, we observed that metformin increased 
the expression of caspase-8 and caspase-9 genes at 24, 48, and 72 h, 
and the maximum effect was observed at 72 h. No effect was 
observed on caspase-3 at any time point. Also, the results showed 
that all three doses, 5, 10, and 50 μM, of metformin increased 
expression of caspase-8 and caspase-9, and the maximum effect 
was observed at a dose of 50 μM. None of the three dose of 
metformin affected caspase-3. In simultaneous survey of 
metformin dose and the incubation time, the most effective dose 
of metformin on gene expression of caspase-8 and caspase-9 
were recorded in 50 μM and 72 h. (Figure 1, Figure 2, and Figure 3) 
Figure 1: Caspase-3, caspase-8, caspase-9, and PARP-1 gene transcription in 
three doses at the 24 h time point. Statistically significant differences of 
caspase-8 and -9 gene expression were observed between metformin (5, 10, 
and 50 μM) and control groups at the 24 h time point (p ≤ 0.001). 
Figure 2: Caspase-3, caspase-8, caspase-9, and PARP-1 gene transcription in 
three doses at the 48 h time point. Statistically significant differences of 
caspase-8 and -9 and PARP-1 gene expression were observed between 
metformin (5, 10, and 50 μM) and control groups at the 48 h time point (p ≤ 
0.001). 
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Figure 3: Caspase-3, caspase-8, caspase-9, and PARP-1 gene transcription in 
three doses at the 72 h time point. Statistically significant differences of 
caspase-8 and -9 and PARP-1 gene expression were observed between 
metformin (5, 10, and 50 μM) and control groups at the 24 h time point (p ≤ 
0.001). 
The results of PARP-1 gene transcription rates in effect of 
metformin at the different time and dose: In this study it was 
observed that metformin on the PARP-1 gene expression is 
unaffected at 24 hours, but at 48 and 72 h increased the 
expression of PARP-1 at three doses 5, 10, 50 μM. In 
simultaneous survey of metformin dose and the incubation time, 
the ma imum effect were recorded in 50 μM and 72 h (Figure 1, 2, 3). 
Discussion 
In this study, we showed that metformin increases gene 
expression of caspase-8 and caspase-9 in breast cancer cells but 
did not affect expression of caspase-3. In other studies, 
metformin activated or elevated expression of caspase-3, -8, 
and -9. This data suggests that metformin affects caspase-3 
activity and the expression of caspase-3 at the protein level but 
does not affect the expression of caspase-3 on the mRNA level. 
Caspase-3 plays a key role in both the death receptor pathway, 
initiated by caspase-8, and the mitochondrial pathway, 
involving caspase 9. In addition, several studies have shown 
that caspase-3 activation is required for apoptosis induction in 
response to chemotherapeutic drugs, e.g., taxanes, 5-
fluorouracil, and doxorubicin.16-18 
In our study we found that metformin has no effect on 
PARP-1 at 24h, but it elevated the expression of PARP-1 at 48 
and 72h. In the other studies (zhaung y 2011, liu b 2009), 
metformin effected PARP-1.While PARP-1 is constitutively 
expressed, its characteristic ability of being activated by DNA 
strand breaks makes poly (ADP-ribosylation) an immediate and 
drastic cellular response to DNA damage as induced by 
ionizing radiation, alkylating agents, and oxidants.19 
Hyperactivation of PARP also may cause cell death by 
depleting cellular NAD+ levels. Because NAD+ is required for 
both glycolysis and oxidative metabolism in mitochondria, 
depletion could lead to cellular energy collapse and subsequent 
cell death.19-21 PARP-dependent cell death of metformin-treated 
cells appears to be delayed relative to apoptotic cell death and 
is associated with changes in mitochondrial morphology.22 This 
study showed that metformin, by increasing the transcription of 
caspase-8 and caspase-9, causes cell death through apoptosis. 
These results indicate that metformin does not affect the 
expression of caspase-3 at any dose. 
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